Alterity Therapeutics Limited (ASX:ATH)
0.0100
+0.0010 (11.11%)
Jul 4, 2025, 4:15 PM AEST
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 1.61M AUD in the half year ending December 31, 2024, a decrease of -32.69%. This brings the company's revenue in the last twelve months to 3.72M, up 8.55% year-over-year. In the fiscal year ending June 30, 2024, Alterity Therapeutics had annual revenue of 4.02M with 2.63% growth.
Revenue (ttm)
3.72M
Revenue Growth
+8.55%
P/S Ratio
24.51
Revenue / Employee
372.45K
Employees
10
Market Cap
91.27M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Ramsay Health Care | 17.12B |
Telix Pharmaceuticals | 783.21M |
Ansell | 3.00B |
Regis Healthcare | 1.10B |
Alterity Therapeutics News
- 12 days ago - Alterity Therapeutics to Provide Corporate Update in Fireside Chat - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Prominently Featured at the International MSA Congress - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Appendix 4C – Q3 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire